Lipoprotein(a) and All-Cause Mortality: Paradox or Arithmetic?

Rather than representing merely an evolutionary remnant with detrimental CV effects, Lp(a) may reflect a complex biological trade-off, conferring CV disadvantage while potentially retaining other physiological functions that may contribute to prolonged survival. Understanding this dual nature of Lp(a) will be essential to optimize risk–benefit assessments of future Lp(a)-lowering therapies and to ensure that CV prevention strategies consider the broader implications of modifying this unique lipoprotein. In the meantime, the discrepancy between cause-specific and all-cause mortality should be read primarily as a lesson in epidemiological interpretation, and only secondarily, and cautiously, as a window onto unrecognized biology. The clinical interpretation of Lp(a) would also benefit from targeted educational materials and harmonized practice guidance. Such resources should explain that elevated Lp(a) is primarily an inherited, causal risk factor for ASCVD and should not be interpreted as a direct predictor of an individual's all-cause mortality. They should distinguish absolute CV risk from cause-specific and all-cause mortality, explain the limitations of composite endpoints, and emphasize that a lack of excess all-cause mortality does not negate the value of CV risk prevention. Educational tools should also address unit differences between mg/dL and nmol/L, the limitations of direct conversion between these units, the importance of considering Lp(a) alongside global CV risk, and the currently uncertain long-term non-CV effects of substantial Lp(a) lowering. Guideline development should be updated as evidence from trial outcome becomes available.